Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Tirzepatide, a dual GIP and GLP-1 receptor agonist, has shown significant metabolic benefits and weight reduction, but its anti-inflammatory effects have been less studied. This study was conducted in accordance with PRISMA guidelines, including observational (cohort) studies and randomized clinical trials that evaluated tirzepatide use and reported percentage changes in high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6). A random-effects model was used. Seven randomized clinical trials and one observational study were included (six studies were eligible for meta-analysis). Compared to placebo, tirzepatide reduced hsCRP (mean difference [MD]: -32.9; 95% confidence interval [CI]: -33.6 to - 32.2; I²=15.3%) and IL-6 (MD: -17.8; 95% CI: -24.3 to - 11.3; I² = 1.6%). Levels of hsCRP were significantly reduced with tirzepatide at 15 mg (MD: -32.9; 95% CI: -33.6 to - 32.2; I²=4.4%), 10 mg (MD: -33.9; 95% CI: -50.3 to - 17.6; I²=41.8%), and 5 mg (MD: -20.3; 95% CI: -35.2 to - 5.3; I²=0%). Similarly, IL-6 levels were significantly reduced with tirzepatide at 5 mg (MD: -18.8; 95% CI: -32.9 to - 4.6; I²=17.2%), 10 mg (MD: -17.9; 95% CI: -28.2 to - 7.7; I²=2.1%), and 15 mg (MD: -16.8; 95% CI: -31.1 to - 2.6; I²=47.4%). This study demonstrated that tirzepatide use is associated with a significant reduction in inflammatory markers, regardless of the population studied or treatment regimen.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, evidence regarding dual incretin agonists such as tirzepatide remains limited and has not been systematically evaluated specifically in T2DM populations [15].”
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Phelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02750-2 · Cited by 2,544
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
Cited by
Kanbay, M., Shah, E., AlShiab, R., Ozbek, L., Ay, S., Rustamov, A., Covic, A., Mallamaci, F., & Zoccali, C. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.71106 · Cited by 4
Khan, S., Herbst, W., Tajrishi, F. Z., Notani, S., Knight, A., Jamil, Z., & Ferdinand, K. C. (2026) · Biomedicines · doi:10.3390/biomedicines14040743 · Cited by 4
“In parallel, a recent meta-analysis of 13 randomized trials (>26,000 participants) showed that semaglutide consistently lowered CRP compared with placebo and other glucose-lowering therapies [58].”
Yang, Z., Xu, Y., Du, H., Liu, W., Chen, H., Liu, D., Zhang, L., & Wang, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70966 · Cited by 8
“This finding aligns with the anti-inflammatory effects of tirze-patide reported by Masson et al., although the changes observed in the MET group differ from those previously reported by Morin-Papunen et al. [31, 32].”
Redefining Cystic Fibrosis-Related Diabetes Management With Tirzepatide: A Case Report
Babu, Y. S., & Jayagopal, V. (2025) · Cureus · doi:10.7759/cureus.97448 · Cited by 2
“As mentioned earlier, it combines the incretin effects of both hormones, and emerging evidence also suggests anti-inflammatory and endothelial benefits, which could be particularly relevant in CF, a condition characterised by systemic inflammation and heightened cardiovascular risk [15].”
Khan, I., Meenakshi, S., Abubakar, M., Kumar, N., Gaikwad, V. L., Rai, A., & Murti, K. (2026) · Endocrine · doi:10.1007/s12020-026-04686-5 · Cited by 2
“Anti-inflammatory and anti - fibrotic actions arise via suppression of NF-κB and JNK, lowering TNF-α, IL-6, and MCP-1, while enhancing IL-10 and adiponectin [119, 120 ].”
Metadata
- Authors
- Masson, W., Lobo, M., Nogueira, J. P., Barbagelata, L., Touzas, P., & Frías, J. P.
- Affiliations
- Hospital Italiano de Buenos Aires (AR)
- Universidad Internacional de las Américas (CR)
- Charles R. Drew University of Medicine and Science (US)
- Corresponding author
- Masson, Walter
- Venue
- Reviews in Endocrine and Metabolic Disorders
- Published
- 2025-10-01
- Volume
- 27
- Issue
- 1
- Pages
- 5-15
- ISSN
- 1389-9155 (ISSN-L)
- 1573-2606
- OpenAlex
- W4414685749
- Semantic Scholar
- 5bdf69e89d4b2c4a623c354af5c9a40e6d38d96d
- Cited by
- 21
- References
- 50
- Citations by year
- 2026: 20 · 2025: 1
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Reviews in Endocrine and Metabolic Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- tirzepatide, anti-inflammatory activity, high-sensitivity C-reactive protein, interleukin-6, GIP/GLP-1 receptor agonist, inflammatory markers, weight loss, obesity
- MeSH terms
- Tirzepatide, Anti-Inflammatory Agents, C-Reactive Protein, Gastric Inhibitory Polypeptide, Humans, Inflammation, Interleukin-6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1007/s11154-025-09991-4
- The paper
- Masson, W., Lobo, M., Nogueira, J. P., Barbagelata, L., Touzas, P., & Frías, J. P. (2026). Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis. Reviews in Endocrine and Metabolic Disorders. https://doi.org/10.1007/s11154-025-09991-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.